[EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].

With the purpose to estimate the efficiency of ursodeoxycholic acid (UDCA) in standard antiviral therapy (SAT) of chronic hepatitis C or/and B 580 patients with the chronic virus hepatitis enrolled in this study. During 48 weeks patients with hepatitis B and B+D received peg-interferon, and patients with C and B+C hepatitis received combined peg-interferon and ribavirin. 1st group of 300 patients (B--130, C--96, B+C--73, B+D--10; 190 men, 110 women, middle age of 32.

[Ciprofloxacin in the treatment of patients with brucellosis].

With the aim to estimate the clinical and immunological efficiency of the ciprofloxacin (cifloxinal) 105 patients with acute (51), subacute (19) and chronic (35) brucellosis were studied. Control group (17 patients with acute and 30 patients with chronic brucellosis) have been treated with combination of two antibiotics: doxycycline and rifampicin. Ciprofloxacin in a dose 500 mg bid within 14 days in acute stage and 20 days in chronic stage of disease essentially reduced duration of local inflammatory processes of brucellosis with simultaneous treatment of the chronic infection focus, provides good proximate and distant outcomes of treatment.

[Efficacy of pefloxacin in the treatment of complicated relapsing erysipelas].

The effect of antimicrobial agents on the clinical and immunological indices was comparatively studied in 30 patients with relapsing erysipelas complicated by pyoderma. The patients were treated with pefloxacin in a daily dose of 800 mg for 7-10 days (15 patients) and with the routine antibiotics such as benzylpenicillin, ampicillin and erythromycin (15 patients). The efficacy of the treatment was defined by disappearance of the clinical signs and normalization of the functional immunity status.

[Pefloxacin mesylate--clinical effectiveness in various forms of infectious-inflammatory diseases].

Pefloxacin mesylate is a broad spectrum fluoroquinolone active against pathogens with multiple resistance. Due to its high therapeutic efficacy (at last 90 per cent) and good tolerance pefloxacin mesylate is considered as the most promising drug in the therapy of severe infections and infections difficult for the treatment such as wound infection, meningitis and particularly perilous infections. Prolonged pharmacokinetics and high bioavailability of the drug provided its administration in the treatment of in- and outpatients with severe infection twice a day in a daily dose of 0.